• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Outcome of Chronic Myeloid Leukemia Patients Not in Deep Molecular Response: Results From the GIMEMA LabNet CML Network Database.

作者信息

Stagno Fabio, Cucci Rosalba, Marsili Giovanni, Castagnetti Fausto, Galimberti Sara, Izzo Barbara, Sorà Federica, Soverini Simona, Messina Monica, Piciocchi Alfonso, Bonifacio Massimiliano, Cilloni Daniela, Iurlo Alessandra, Martinelli Giovanni, Rosti Gianantonio, Fazi Paola, Vignetti Marco, Breccia Massimo, Allegra Alessandro, Pane Fabrizio

机构信息

Hematology Section, AOU Policlinico "G. Martino", University of Messina, Messina, Italy.

GIMEMA Foundation, Rome, Italy.

出版信息

Am J Hematol. 2025 Aug;100(8):1467-1470. doi: 10.1002/ajh.27733. Epub 2025 Jun 5.

DOI:10.1002/ajh.27733
PMID:40470709
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12232560/
Abstract
摘要

相似文献

1
Outcome of Chronic Myeloid Leukemia Patients Not in Deep Molecular Response: Results From the GIMEMA LabNet CML Network Database.未达到深度分子反应的慢性髓性白血病患者的预后：来自GIMEMA实验室网络慢性髓性白血病网络数据库的结果
Am J Hematol. 2025 Aug;100(8):1467-1470. doi: 10.1002/ajh.27733. Epub 2025 Jun 5.
2
Deep Molecular Response Rate in Chronic Phase Chronic Myeloid Leukemia: Eligibility to Discontinuation Related to Time to Response and Different Frontline TKI in the Experience of the Gimema Labnet CML National Network.慢性期慢性髓性白血病的深度分子反应率：在Gimema实验室网络慢性髓性白血病国家网络经验中与反应时间和不同一线酪氨酸激酶抑制剂相关的停药资格
Clin Lymphoma Myeloma Leuk. 2025 Jan;25(1):e34-e39. doi: 10.1016/j.clml.2024.08.009. Epub 2024 Sep 7.
3
Chronic myeloid leukemia outcomes according to baseline risk and first-line treatment in real-world settings: Data from the Italian Network/CML Campus.真实世界中慢性髓系白血病根据基线风险和一线治疗的结局：来自意大利网络/CML校园的数据。
Cancer. 2025 Jul 1;131(13):e35963. doi: 10.1002/cncr.35963.
4
A Systematic Review on Second Treatment-Free Remission (TFR) Attempt in Chronic Myeloid Leukemia (CML): Can it be Applied in Clinical Practice?一项关于慢性髓性白血病（CML）中第二次无治疗缓解（TFR）尝试的系统评价：它能否应用于临床实践？
Clin Lymphoma Myeloma Leuk. 2023 Jan;23(1):8-14. doi: 10.1016/j.clml.2022.09.004. Epub 2022 Oct 5.
5
Management of chronic myeloid leukemia in 2025.2025年慢性髓性白血病的管理
Cancer. 2025 Jul 15;131(14):e35953. doi: 10.1002/cncr.35953.
6
Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation.达沙替尼和尼洛替尼治疗伊马替尼耐药或不耐受的慢性髓性白血病：系统评价和经济评估。
Health Technol Assess. 2012;16(22):1-410. doi: 10.3310/hta16220.
7
Maternal and Foetal Outcomes of Newly Diagnosed Chronic Myeloid Leukemia During Pregnancy and its Long-Term Impact.孕期新诊断慢性髓性白血病的母婴结局及其长期影响
Indian J Hematol Blood Transfus. 2024 Oct;40(4):687-693. doi: 10.1007/s12288-024-01743-9. Epub 2024 Apr 5.
8
Metabolomic Profiling and Bioanalysis of Chronic Myeloid Leukemia: Identifying Biomarkers for Treatment Response and Disease Monitoring.慢性髓性白血病的代谢组学分析与生物分析：确定治疗反应和疾病监测的生物标志物
Metabolites. 2025 Jun 6;15(6):376. doi: 10.3390/metabo15060376.
9
Chronic Myeloid Leukemia following Exposure to Radioactive Iodine (I131): A Systematic Review.放射性碘（I131）暴露后慢性髓性白血病：系统评价。
Oncology. 2023;101(6):362-368. doi: 10.1159/000530463. Epub 2023 May 9.
10
Comparative Effectiveness of Newer Tyrosine Kinase Inhibitors Versus Imatinib in the First-Line Treatment of Chronic-Phase Chronic Myeloid Leukemia Across Risk Groups: A Systematic Review and Meta-Analysis of Eight Randomized Trials.新型酪氨酸激酶抑制剂与伊马替尼在不同风险组慢性期慢性髓性白血病一线治疗中的疗效比较：八项随机试验的系统评价和荟萃分析
Clin Lymphoma Myeloma Leuk. 2016 Jun;16(6):e85-94. doi: 10.1016/j.clml.2016.03.003. Epub 2016 Mar 30.

本文引用的文献

1
The Evolution of Treatment-Free Remission.无需治疗的缓解状态的演变
Blood. 2025 Jan 6. doi: 10.1182/blood.2024026310.
2
Novel treatment strategies for chronic myeloid leukemia.慢性髓性白血病的新型治疗策略
Blood. 2025 Feb 27;145(9):931-943. doi: 10.1182/blood.2024026312.
3
Long-term outcomes of tyrosine kinase inhibitors in chronic myeloid leukemia.酪氨酸激酶抑制剂治疗慢性髓性白血病的长期疗效
Blood. 2025 Feb 27;145(9):910-920. doi: 10.1182/blood.2024026311.
4
European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia.欧洲白血病网络实验室关于慢性髓性白血病诊断和管理的建议。
Leukemia. 2023 Nov;37(11):2150-2167. doi: 10.1038/s41375-023-02048-y. Epub 2023 Oct 4.
5
Survival with chronic myeloid leukaemia after failing milestones.失败里程碑后慢性髓性白血病的生存。
Leukemia. 2023 Nov;37(11):2231-2236. doi: 10.1038/s41375-023-02028-2. Epub 2023 Sep 19.
6
Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis.一线尼洛替尼对比伊马替尼治疗初诊慢性期慢性髓性白血病的长期疗效：ENESTnd 研究 10 年分析。
Leukemia. 2021 Feb;35(2):440-453. doi: 10.1038/s41375-020-01111-2. Epub 2021 Jan 7.
7
On the road to treatment-free remission in chronic myeloid leukemia: what about 'the others'?在慢性髓性白血病的无治疗缓解之路上：“其他人”如何？
Expert Rev Anticancer Ther. 2020 Dec;20(12):1075-1081. doi: 10.1080/14737140.2020.1829483. Epub 2020 Oct 8.
8
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.欧洲白血病网络 2020 年治疗慢性髓性白血病的建议。
Leukemia. 2020 Apr;34(4):966-984. doi: 10.1038/s41375-020-0776-2. Epub 2020 Mar 3.
9
Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV.定义慢性髓性白血病主要分子缓解的治疗目标：CML 研究 IV 的随机结果。
Leukemia. 2018 May;32(5):1222-1228. doi: 10.1038/s41375-018-0055-7. Epub 2018 Feb 26.
10
Molecular monitoring in chronic myeloid leukemia-how low can you go?慢性髓性白血病的分子监测——你能降至多低？
Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):156-163. doi: 10.1182/asheducation-2016.1.156.